Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04995653 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
A Phase 1 study, sponsored by Seres Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT04995653 is a Phase 1 study that has completed, run by Seres Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT04995653, a Phase 1 study, has completed, sponsored by Seres Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease
Interventions
- DRUG Vancomycin Pre-Treatment
- DRUG Vancomycin Placebo
- DRUG SER-155
- DRUG SER-155 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-11-24 |
| Est. Completion | 2024-07-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04995653
The ClinicalTrials.gov registry entry for NCT04995653 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seres Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vancomycin Pre-Treatment is the first listed.
NCT04995653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04995653 about?
NCT04995653 is a clinical study titled "A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT". An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease
What is the current status of trial NCT04995653?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-11-24. Estimated completion is 2024-07-23.
What interventions are being tested in trial NCT04995653?
The interventions under investigation include: Vancomycin Pre-Treatment (DRUG), Vancomycin Placebo (DRUG), SER-155 (DRUG), SER-155 Placebo (DRUG).
Who is sponsoring clinical trial NCT04995653?
This trial is sponsored by Seres Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.